Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HWS116 in advanced solid tumors
NCT07413328Phase 1Recruiting
- Sponsor
- Humanwell Healthcare Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HWS116 in solid tumor, sponsored by Humanwell Healthcare Group Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years and Objective Response Rate at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
HWS116
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07413328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413328.